Instrumento Inactivo

Otros idiomas ChemoCentryx, Inc.

Acciones

CCXI

US16383L1061

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index	24/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index	24/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index	24/10/22
HBM Healthcare rutscht im H1 2022/23 mit 34 Millionen Franken in Verlustzone	21/10/22
HBM Healthcare confirme une perte semestrielle de 34,2 millions	21/10/22
Amgen Completes ChemoCentryx Acquisition	20/10/22
CHEMOCENTRYX, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20/10/22
Chemocentryx, Inc. Announces Executive Changes	20/10/22
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX	20/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index	20/10/22
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.	20/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index	19/10/22
CHEMOCENTRYX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	18/10/22
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	17/10/22
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	17/10/22
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting	05/10/22
HBM Healthcare prévoit une perte de 34 millions au 1er semestre 2022/23	03/10/22
HBM Healthcare erwartet für H1 2022/23 Nettoverlust von rund 34 Mio Fr.	03/10/22
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	28/09/22
CHEMOCENTRYX, INC. : Other Events (form 8-K)	20/09/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas ChemoCentryx, Inc.

Acciones

CCXI

US16383L1061

Otros idiomas

Filtros